<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01337531</url>
  </required_header>
  <id_info>
    <org_study_id>rFSH.- HP-FSH.PCOS</org_study_id>
    <nct_id>NCT01337531</nct_id>
  </id_info>
  <brief_title>Recombinant Versus Highly Purified FSH in Polycystic Ovary Syndrome (PCOS)</brief_title>
  <official_title>Recombinant FSH Versus Highly Purified FSH in PCOS Patients Undergoing Control Ovarian Stimulation and IVF: a Prospective Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genesis Center for Fertility &amp; Human Pre-Implantation Genetics</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genesis Center for Fertility &amp; Human Pre-Implantation Genetics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Control ovarian stimulation responses, pregnancy and miscarriage rates are indifferent when
      either recombinant or highly purified follicle stimulating hormone (FSH) is used.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized using sealed and numbered envelopes and will be assigned to
      receive a similar ovarian stimulation regime incorporating either Gonal-F or highly purified
      Fostimon as the hormonal analog. Ovarian response using either of the two compounds,
      pregnancy rates and miscarriage rates will be compared to define possible statistical
      significance.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ovarian Response</measure>
    <time_frame>0-15 days post gonadotropin administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>12-15 days post embryo replacement</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>gonadotropin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>recombinant or highly purified gonadotropin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gonadotropins</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>recombinant versus highly purified gonadotropin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gonal-F, Fostimon</intervention_name>
    <description>dosage form</description>
    <arm_group_label>gonadotropin</arm_group_label>
    <other_name>Recombinant Gonadotropin, Highly purified Gonadotropin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gonal-F, Fostimon</intervention_name>
    <description>injection, daily, 10-15 days</description>
    <arm_group_label>Gonadotropins</arm_group_label>
    <other_name>Gonal-F</other_name>
    <other_name>Fostimon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PCOS

          -  Primary infertility

          -  No other fertility manifestation

        Exclusion Criteria:

          -  Non PCOS

          -  Secondary infertility
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Savvas N Koundouros, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Genesis Center for Fertility and Human Pre-implantation Genetics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Genesis Centre for Fertility and Human Pre-implantation Genetics</name>
      <address>
        <city>Limassol</city>
        <zip>3025</zip>
        <country>Cyprus</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cyprus</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2011</study_first_submitted>
  <study_first_submitted_qc>April 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2011</study_first_posted>
  <last_update_submitted>April 18, 2011</last_update_submitted>
  <last_update_submitted_qc>April 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Savvas Koundouros</name_title>
    <organization>Responsible party is an organization</organization>
  </responsible_party>
  <keyword>Ovarian Response in PCOS</keyword>
  <keyword>pregnancy rate in PCOS</keyword>
  <keyword>miscarriage rate in PCOS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

